Dr. David Richardson, MD, a Board-certified Ophthalmologist and Eye Doctor in Los Angeles focussed on his website on the role Palmitoylethanolamide (PeaPure) can play in the treatment of hypertension of the eye ball, glaucoma. Dr. Richardson is a recognized and respected, cataract and glaucoma surgeon; and is among an elite group of eye surgeon in the country performing the highly specialized canaloplasty procedure.
On his website on new treatments for glaucoma he entered a new chapter:
Evidence that Palmitoylethanolamide (PEA) can be used to treat glaucoma
We quote from his website:
PEA is naturally found in the ciliary body (the eye tissue that produces aqueous fluid). In patients with glaucoma there is a reduced amount of PEA in the ciliary body. It stands to reason that if patients with glaucoma have less PEA in their eyes then perhaps increasing the amount of PEA could treat glaucoma.
Indeed, there are now multiple studies in which PEA has been shown to lower the intraocular pressure (IOP). Studies published in 2011 and 2013 comparing PEA against placebo demonstrated a statistically significant reduction in IOP with the use of PEA (which was not seen with the placebo). A separate study was presented at an international meeting in 2013. In this study patients that received PEA had lower IOP and were less likely to lose vision.
Palmitoylethanolamide’s Potential Side Effects and Risks
As reported in the most recent study, PEA was “safe and well tolerated, with no drug-related adverse effects .” Earlier studies have also noted the lack of significant side effects.
In the most recent study, patients were instructed to take 300mg of PEA by mouth twice daily.
Cost of Palmitoylethanolamide (PEA)
PEA is not cheap. However, if you are interested in taking Palmitoylethanolamide (PEA) as a natural treatment for glaucoma, the commercially available form (PeaPureTM) is $30-40 for a package of 30 (thirty) 400mg capsules. As the study evaluated patients who took a total of 600mg a day the monthly cost of this treatment would be $45-60/month.
More on glaucoma
Glaucoma is a multi-factorial optic neuropathy of unknown aetiology in which the increased intraocular pressure is the most important risk factor, but also ischaemia, vascular dysregulation, vasospasm and endothelial dysfunction, may prevent the physiological regulation of ocular blood flow, determining modifications in the optic nerve head supply, contributing to the damage of the ganglion cells.
Therapeutically, therefore, both reducing intra ocular pressure (IOP) and improving ocular blood flow may be considered as treatment options both in glaucoma and ocular hypertension. It’s feasible that ameliorating endothelial function may contribute to improve optic nerve head blood supply and to reducing susceptibility of Orthotopic heart transplantation (OHT) patients to develop glaucoma or of glaucoma patients to progress more rapidly.
Palmitoylethanolamide belongs to the lipid signaling sytem and it is implicated in the physiology of different human systems, included ocular tissues and vascular system where seems to exert, among others, an important role in the endothelial protection thus could play a main role in the treatment of glaucoma or OHT patients.
The ophtalmologists Strobbe et al proved in 2013 that:
Three-month PEA intake reduced Inta Ocular Pressure and led to significantly improved flow-mediated vasodilation (FMD) values in OH patients compared to placebo, by ameliorating peripheral endothelial function, and its positive effect lasted longer than the period of PEA consumption. No adverse events were recorded.
Lambert DM, Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem. 1999;6:757–773.
Bachur NR, Masek K, Melmon KL, Udenfriend S. Fatty acid amides of ethanolamine in mammalian tissues. J Biol Chem.1965;240:1019–1024..
Kuehl FA, Jacob TA, Ganley OH, Ormond RE, Meisinger MAP. The identiﬁcation of N-(2-hydroxyethyl)-palmitamide as a naturally oc-curring anti-inﬂammatory agent. J Am Chem Soc. 1957;79:5577–5578..
Buchwald A, Browne CE, Wu WM, Ji F, Bodor N. Soft cannabinoid analogues as potential anti-glaucoma agents. Pharmazie. 2000;55:196–201..
Chen J, Matias I, Dinh T, et al. Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun. 2005;330:1062–1067..
D. C. Gagliano et al., Invest. Ophthalmol. Vis. Sci., 2011;52(9):6096–6100.
Gagliano, D. C. (2013). A new treatment paradigm for POAG? Ophthalmology Times Europe.
Strobbe E, Cellini M, Campos EC. Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study.Invest Ophthalmol Vis Sci. 2013 Feb 1;54(2):968-73. doi: 10.1167/iovs.12-10899.